Pharmacogenetics in ovarian stimulation - current concepts and future options.
Tailoring ovarian stimulation to the individual patient can be challenging because the ovarian response varies substantially between patients. Pharmacogenetics has emerged as a new area of research to improve the balance between desired and undesired actions of drugs, based upon the genetic predisposition of the individual patient. Clinical studies have demonstrated that the p.N680S polymorphism of the FSH-receptor gene determines the ovarian response to FSH stimulation in patients undergoing IVF. In homozygous Ser(680)/Ser(680) type women, the FSH receptor appears to be more resistant to FSH action even in normal menstrual cycles. Therefore, genotyping of patients scheduled for ovarian stimulation could be an attractive tool to individualize FSH dosing according to genetic differences in ovarian sensitivity. More clinical studies are warranted to investigate the usefulness of genotyping for the p.N680S polymorphism as a routine diagnostic test before ovarian stimulation.
Greb
Robert R
RR
Muenster University Hospital, Germany. robert.greb@uni-muenster.de
Behre
Hermann M
HM
Simoni
Manuela
M
D004305:Dose-Response Relationship, Drug; D005260:Female; D005300:Fertility Agents, Female / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage / Q000627:therapeutic use*; D005544:Forecasting; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy* / Q000235:genetics; D010062:Ovulation Induction / Q000379:methods / Q000639:trends*; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D011962:Receptors, FSH / Q000235:genetics* / Q000502:physiology; D012694:Serine / Q000235:genetics
D005300:Fertility Agents, Female; D011962:Receptors, FSH; D012694:Serine; D005640:Follicle Stimulating Hormone